Bruns Ingmar reported grant involving 9,727 shares of Zentalis Pharmaceuticals, Inc. at $2.18 for $21.2k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Medical Officer
Chief Medical Officer
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$21,204.86Shares × reported price
Shares traded
9,727Common Stock
Price per share
$2.18Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
43,059Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 1, 2026, 5:19 PM ET1-day reporting delay
Accession
0001628280-26-064317Code A · Transaction 233147
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ZNTL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ZNTL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +21%1w ago 0%1d ago 0%
Returns since7d −20%30d −37%90d180d1y

Footnotes in full

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026.